ReviewNature reviews. Disease primers2022
Hepatic encephalopathy.
Review in Nature reviews. Disease primers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 114 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
114 citing papers in PubMed, 3 syntheses or guidelines pooled it, 195 citations in OpenAlex.
- Risk prediction models for hepatic encephalopathy in patients with liver cirrhosis: a systematic review and meta-analysis.BMC gastroenterology · 2026Pooled it
- Efficacy and safety of rifaximin in preventing hepatic encephalopathy: A systematic review and meta-analysis.PloS one · 2025Pooled it
- Preventive and therapeutic effects of rifaximin on hepatic encephalopathy with differential application dosages and strategies: a network meta-analysis.BMC gastroenterology · 2024Pooled it
- Differential metabolic and cellular brain regional susceptibility in adult rats with chronic liver disease.Metabolic brain disease · 2026Article
- Uncovering immune dysfunction in ACLF: Cellular mechanisms, molecular pathways, and therapeutic frontiers.Journal of hepatology · 2026Review
- Interorgan Crosstalk in MASLD: A Narrative Review.Biomedicines · 2026Review
- XGBoost-SHAP Interpretable Modeling Identifies and Validates an Eight-Gene Biomarker for Hepatic Encephalopathy Risk Prediction in Cirrhosis.International journal of molecular sciences · 2026Article
- Neurofilament Light Chain in Cerebrospinal Fluid and Blood Identifies Patients With Minimal and Overt Hepatic Encephalopathy.Liver international : official journal of the International Association for the Study of the Liver · 2026Article
- Review
- The Challenge of Determining the Etiology of Encephalopathy in an Elderly Patient.Clinical case reports · 2026Article
- Article
- Multi-organ non-contrast computed tomography radiomics model to predict hepatic encephalopathy in patients with cirrhosis and hepatorenal failure.Diagnostic and interventional radiology (Ankara, Turkey) · 2026Article
- Reducing the Risk of Overt Hepatic Encephalopathy Recurrence: A Narrative Review.Journal of clinical and translational hepatology · 2026Review
- Extracellular vesicles from plasma of patients with minimal hepatic encephalopathy induce neuroinflammation and cognitive impairment in rats, which are prevented by treating the patients with rifaximin.Journal of neuroinflammation · 2026Article
- Liver-nervous system axis: pathways, dysregulation, and translational perspectives.Journal of neuroinflammation · 2026Review
- Association between bedroom nighttime light pollution and risk of hepatic encephalopathy in hepatocellular carcinoma patients: a prospective cohort study.Scientific reports · 2026Article
- Article
- A Novel Use of Tenapanor in Patients With Hepatic Encephalopathy: A Case Series.ACG case reports journal · 2026Article
- Role of cerebral blood flow changes in post-transjugular intrahepatic portosystemic shunts hepatic encephalopathy.World journal of radiology · 2026Article
- Activation of SNr GABA neurons drives liver-brain-eye axis dysfunction in hepatic encephalopathy.iScience · 2026Article
54 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 11 institutions in 6 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatic encephalopathy (HE) is a prognostically relevant neuropsychiatric syndrome that occurs in the course of acute or chronic liver disease. Besides ascites and variceal bleeding, it is the most serious complication of decompensated liver cirrhosis. Ammonia and inflammation are major triggers for the appearance of HE, which in patients with liver cirrhosis involves pathophysiologically low-grade cerebral oedema with oxidative/nitrosative stress, inflammation and disturbances of oscillatory networks in the brain. Severity classification and diagnostic approaches regarding mild forms of HE are still a matter of debate. Current medical treatment predominantly involves lactulose and rifaximin following rigorous treatment of so-called known HE precipitating factors. New treatments based on an improved pathophysiological understanding are emerging.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.